You can access any of the podium or poster presentations’ abstracts by searching for it below.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
THE USAGE EVALUATION OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN A LOCAL HOSPITAL OF TAIWAN
- In: Poster Session
- At: Düsseldorf (Germany) (2015)
- Type: Poster
- By: CHANG, Hsiu-Mei (Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, pharmacy department, Kaohsiung City, China Taiwan)
- Co-author(s): Hsiu-Mei Chang
- Abstract:
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is orally used in diabetes. It was approved by FDA in 2006 to control blood sugar in patients with type-2 diabetes mellitus (T2DM). The usage has gradually increased since 2010 started in our hospital.Due to its high cost, Sitagliptin has become the second highest annual cost of oral medication..
The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 2 July 2026